- Review
- Open access
- Published:
Clinical and laboratory manifestations, ECG findings, and outcomes of right atrial myxoma: a systematic review of cases reported worldwide
The Egyptian Heart Journal volume 76, Article number: 125 (2024)
Abstract
Background
The presence of cardiac myxoma in the right atrium (RA) is rare. There is limited knowledge regarding the clinical symptoms and diagnosis of RA myxoma. This systematic review aimed to provide a summary of the clinical and laboratory characteristics, electrocardiogram (ECG) findings, and outcome previous cases with RA myxoma.
Methods
A comprehensive search was conducted in PubMed, Web of Science, and Scopus to identify relevant studies. Inclusion criteria were case reports and case series written in English that provided sufficient data on the manifestation of RA myxoma. Descriptive statistics were used for quantitative analysis.
Results
The search identified 619 patients from 480 eligible studies. The patient’s mean age was 45.7 ± 17.6 years, and 55.4% of cases were female. The most common clinical manifestations of RA myxoma were cardiac, systemic, and neurologic manifestations which reported in 77.0%, 34.8%, and 21.1% of cases, respectively. Besides, 11.7% of RA myxoma were asymptomatic. ECG findings revealed normal in 39.4% reported cases. The ECG abnormalities included tall or peaked P-wave, RA and LA enlargement (19.2%), abnormal T-wave (14.0%), sinus tachycardia (11.8%), and incomplete or complete RBBB (11.2%). Echocardiography remained the diagnostic method in a majority of the cases. The mortality rate of RA myxoma was low (9.2%) during the follow-up.
Conclusions
This systematic review provides a comprehensive summary of the clinical and laboratory manifestations and outcomes of RA myxoma, contributing to the existing knowledge on this rare cardiac tumor.
Background
Cardiac masses are a rare group of disorders, with primary tumors and metastatic cancers being the main types. Primary cardiac masses account for about 1 out of 2000 autopsies and consist of both benign (80%) and malignant (20%) tumors [1, 2]. Among benign cardiac neoplasms, myxoma is the most common type, with a prevalence of 50% [3].
The symptoms of cardiac myxoma can vary depending on factors such as location, size, shape, and growth rate [4]. Patients with cardiac myxoma may experience multiple embolic events, such as stroke and pulmonary thromboembolism, due to the immobility of the tumor leading to infarctions [4, 5]. In addition, neurologic symptoms like syncope, psychiatric presentations, headache, and seizures are also common in patients with cardiac myxoma [6]. Cutaneous manifestations of cardiac myxoma can included erythematous, livedo reticularis, and macules [7, 8]. Hence, these varied symptoms and manifestations can make the diagnosis of cardiac myxoma challenging, as they can often mimic other conditions such as heart failure, arrhythmias, or even psychiatric disorders. Therefore, obtaining a thorough medical history, conducting a physical examination, and performing necessary diagnostic tests such as echocardiography, cardiac MRI, or biopsy are crucial for an accurate diagnosis of cardiac myxoma and to determine the optimal treatment approach.
Although there is previous research investigating left atrial myxoma, mitral valve, and pulmonary valve myxomas [9,10,11], prior attention to right atrial (RA) myxoma is limited. A study by Kuon et al. [12] suggests that RA myxoma can have various symptoms like lasting fever, weight loss, chronic anemia, and general arthralgia. Infection of myxoma and myocardial tamponade can develop because of misdiagnosing several complications of this disease like pulmonary hypertension, a Budd-Chiari syndrome with acute abdominal pain. These complications caused by misdiagnosis underline the need for a detailed evaluation of the right RA myxoma to prevent misdiagnoses and complications. In this systematic review, we aimed to summarize demographic data, signs and symptoms, laboratory and electrocardiogram (ECG) findings, and diagnostic methods published in previous case reports to claim better insight into this rare condition.
Methods
This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline [13].
Search strategy
To identify eligible studies, a comprehensive search was conducted in September 2022 on PubMed, Web of Science, and Scopus. The search used the keywords “Cardiac myxoma” OR “Atrial myxoma” OR “Right atrial myxoma.” Additionally, a thorough reviews of the reference lists of qualified articles and google scholar were performed to identify any relevant missing articles.
Eligible criteria
The screening process of the articles involved two reviewers assessing the titles, abstracts, and full-texts, with conflicts determined by another reviewer. Inclusion criteria encompassed case reports and case series written in English that provided sufficient data on the manifestation of right atrial myxoma. Exclusion criteria included books, editorials, reviews, experimental studies, congress abstracts, non-English articles, and case reports and case series that lacked adequate information on the clinical manifestation of right atrial myxoma. Studies involving animals were also excluded. There were no limitations on publication time or the age of participants.
Data extraction
Data extraction was performed separately by two reviewers, incorporating the following categories: (i) bibliographic information (author, year of publication, study type, and country), (ii) demographics (number of patients, gender, age, and comorbidities), (iii) clinical manifestations categorized as cardiac, thromboembolic, neurologic, cutaneous, and systemic, (iv) diagnostic methods, (v) laboratory data (white blood cell (WBC), international normalized ratio (INR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), troponin, and aminoterminal pro B-type natriuretic peptide (NT-proBNP)), (vi) ECG findings, and (vii) outcome. An elevated WBC count is defined as a count greater than 11,000 cells/μL [14]. The normal range for ESR in women is 0–20 mm/h, while in men it is 0–15 mm/h [15]. A CRP level higher than 0.9 mg/dL is considered elevated [16]. The normal limit for troponin-I is considered to be under 0.04 ng/Ml and troponin-T is considered to be under 0.01 ng/Ml [17]. Any conflicts or disagreements during the data extraction process were addressed and resolved by another reviewer. The clinical manifestations are divided into five groups including cardiac (palpitation, dyspnea, chest pain, raised jugular venous pressure, and ankle edema and hepatomegaly due to right-sided heart failure), thromboembolic (pulmonary thromboembolism, cerebral embolism, deep or superficial vein thrombosis, and systemic embolism), cutaneous (erythematous, livedo reticularis, peripheral or central cyanosis, pigmentation, and macules), neurologic (headache, seizure, vertigo, loss of consciousness, non-cardiac syncope, and psychiatric presentation) and systematic (fatigue, malaise, myalgia, weight loss, thrombocytopenia, anemia, and fever).
Quality assessment
The methodological quality of the included case reports and case series was assessed using the Mayo Evidence-Based Practice Center tool [18]. The assessment involved evaluating bias in four domains: selection, ascertainment, causality, and reporting. Each question was scored as 0 or 1, resulting in an overall score ranging from 0 to 8. Based on the final score, each study was categorized as having a high risk (≤ 4), moderate risk (5–6), or low risk (≥ 7) of bias. Among these studies, 179 case reports were categorized as high risk, 173 as moderate risk, and 145 studies as low risk.
Statistical analysis
We performed a quantitatively analyzed using descriptive statistics. Categorical and continuous variables were presented as frequency (percentage) and mean ± standard deviation (SD), respectively. The descriptive analysis was performed using SPSS, version 26.
Results
Study selection and characteristics
The first screening identified 11,040 papers in the PubMed, Scopus, and Web of Science. After removing duplicates and excluding based on title abstract screening, 808 record remained for full-text evaluation. Overall, 480 studies included 619 patients met eligible criteria for inclusion in this systematic review (Fig. 1). A summary of included case reports and case series characteristics are presented in Table S1. The year of publication ranged from 1949 to 2022, and studies were originated from 67 countries. The USA accounts for 179 cases (28.9%), followed by India (10.0%) and China (9.0%) (Figs. 2 and 3).
Patient demographics
The age of cases ranged from early infant to 89 years, with a mean of 45.7 ± 17.6 years, of whom 257 (44.5%) were male. The age distribution of the cases showed that RA myxoma is more prevalent in adult population, with only 39 cases were under 18 years. The most common comorbidity presents in was hypertension (19.2%) followed by diabetes mellitus (7.6%), and other malignancies (6.8%). Among reported studies, 48 patients (7.75%) presented other locations of myxoma.
Diagnostic methods
Echocardiography was the most common primary imaging method for RA myxoma diagnosis, which performed in 428 (77.8%) patients. Computed tomography (CT) scan (26.6%), angiocardiography (19.7%), and cardiac magnetic resonance imaging (MRI) (16.9%) were other reported diagnostic imaging modalities (Table 1).
Clinical manifestations
A wide range of clinical manifestations were reported in the included studies. We divided clinical manifestation into five groups including cardiac, thromboembolic, neurologic, cutaneous, and systemic manifestation. The proportion of each manifestation is presented in Fig. 4. Out the clinical manifestation, cardiac was the most common reported in 477 (77.0%) of cases, followed by systemic manifestation (n = 216 (34.8%)), neurologic manifestations (n = 131 (21.1%)), and thromboembolic events (n = 89 (12.9%)). Besides, 73 (11.7%) cases were diagnosed without any sign and symptoms (Table 2). Syncope was the most common neurological symptom, occurring in 78 cases (59%). Pulmonary embolism was the most frequent thromboembolic event, accounting for 76 cases (85%), followed by multifocal and systemic embolism, which occurred in six cases (6.7%).
Laboratory findings
Leukocytosis was reported in 44 RA myxoma patients, which identified in 50.0% of reported cases. Moreover, 79.2% and 93.4% of measuring studies showed an increased level of ESR and CRP, respectively. NT-proBNP level was elevated in 12 (92.3%) of patients. Troponin level was elevated only in one (10%) case. All reported cases had elevated INR (Table 3).
Electrocardiogram findings
Out of 337 cases with available ECG data, ECG was normal in 133 (39.4%) of patients. The most commonly reported ECG abnormality were the composite of tall or peaked P-wave, RA and LA enlargement (19.2%), abnormal T-wave (14.0%), sinus tachycardia (11.8%), and incomplete or complete RBBB (11.2%). Besides, ST depression and ST elevation were observed in two and three patients, respectively (Table 4).
Outcome
A total of 486 cases reported outcome of the patients. Pooled survival rate of these patients was 90.75%. Among the 45 reported deaths, 19 (42.2%) cases were men and 26 (57.73%) cases were women (Table 1). Among these reported deaths, 5 (11.1%) cases were less than 20 years old, 18 (40.0%) cases were between 20 and 40 years old, 16 (35.6%) cases were 40–60 years old and 6 (13.3%) cases were older than 60 years old.
Discussion
This systematic review summarized the characteristics, outcome, and manifestations of patients with RA myxoma. This study included 480 studies which comprised 619 patients diagnosed with RA myxoma. RA myxoma is a rare condition. Although it may be found in asymptomatic patients, it may be presented with various clinical manifestations including cardiac, systemic, neurological, thromboembolic, and cutaneous symptoms. Increased NT-proBNP and inflammatory markers such as WCB count, CRP, and ESR are reported in patients with RA myxoma. ECG abnormalities were also observed in a significant number of patients, with tall or peaked P-waves, signs of RA and LA enlargement, abnormal T-waves, sinus tachycardia, and RBBB being the most commonly reported findings. The overall survival rate of patients with RA myxoma was high at 90.75%. RA myxoma was uncommon in pediatric cases in this study, with only 39 cases were under 18 years old. Moreover, we found a slight domination by females in RA myxoma patients.
That is in line with previous findings suggestive of a slightly higher prevalence of cardiac myxoma among women [19]. However, these investigations evaluated all cases of cardiac myxoma, whereas our review especially focused on the right atrial myxoma. Additionally, this study identified cardiovascular symptoms as the most common clinical manifestation, which supports our findings that cardiac symptoms are the most prevalent manifestation. However, we have categorized cardiovascular symptoms experienced by patients into cardiac and thromboembolic events. Although cardiac symptoms are more common in these patients, embolization, considering its fetal outcomes and high assurance, needs particular attention.
In this study, we found that 12.9% of the patients with RA myxoma have presented thromboembolic events, which included pulmonary, multifocal, and cerebral embolism. Previous studies also demonstrated atypical location of cardiac myxoma is associated with increased risk of embolic events in these patients [20, 21]. Hence, RA myxoma should be considered in the differential diagnosis of cases with multiple thromboembolic events.
After cardiac symptoms, systemic and neurologic symptoms presented the highest prevalence, respectively. However, a study on left atrial myxoma suggested that constitutional symptoms like fatigue are the least prevalent [22]. Another study suggested a 50% prevalence of constitutional symptoms and 26–45% of neurologic symptoms among left myxoma patients, which are both higher compared to our result [23]. These discrepancies may highlight the potential differences between symptoms of right and left atrial myxoma and warrant further research in this regard.
The amount of death among these cases with RA myxoma was low (9.25%). This suggests that early detection and surgical removal of the tumor can lead to favorable outcomes. However, it is essential to note that delayed diagnosis or complications related to the tumor, such as embolization, may increase the risk of mortality [24,25,26]. Therefore, prompt diagnosis and timely intervention are crucial in the management of RA myxoma.
RA myxoma may be asymptomatic, and hence, could be found incidentally on imaging modalities. Echocardiography remained the primary diagnostic method for RA myxoma in the majority of cases. Previous studies showed the sensitivity of echocardiography as high as 95% for transthoracic echocardiography (TTE) and 100% for transesophageal echocardiography in detection of cardiac myxoma [27, 28]. TTE was the initial imaging modality used in most cases, followed by TEE for further evaluation. TEE was particularly useful in cases where TTE findings were inconclusive or when there was high clinical suspicion for RA myxoma. Other imaging modalities such as cardiac MRI and CT scan were used in a minority of cases. However, it is important to note that echocardiography remains the gold standard for diagnosing cardiac myxomas.
This is the first systematic review evaluated the clinical, laboratory, and ECG findings of patients with RA myxoma, and provides valuable insights into the clinical characteristics and outcomes of patients with RA myxoma and can contribute to the development of evidence-based management strategies for this rare cardiac tumor. The comprehensive search conducted across prominent databases enhances the reliability of this study. This study has some limitations. Firstly, only case reports and case series were included in this systematic review, introducing a potential risk of bias. Secondly, there were lack of data regarding some the required information in most of the included studies. Thirdly, most of included studies (90.75%) reported positive outcome, hence, publication bias should be considered. Finally, despite efforts to conduct a comprehensive literature search, there is a possibility of missing relevant studies due to limitations in the search strategy or databases used.
Conclusions
In conclusion, this systematic review provides a comprehensive summary of the clinical and laboratory manifestations and outcomes of RA myxoma, contributing to the existing knowledge on this rare cardiac tumor. RA myxoma presents with a wide range of clinical symptoms, and ECG findings can aid in the diagnosis. Echocardiography remains the mainstay of diagnosis, while early surgical intervention can lead to favorable outcomes. Further research and larger studies are needed to enhance our understanding of this rare cardiac tumor and to improve diagnostic and management strategies.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- AF:
-
Atrial fibrillation
- CRP:
-
C-reactive protein
- CT:
-
Computed tomography
- ECG:
-
Electrocardiogram
- ESR:
-
Erythrocyte sedimentation rate
- INR:
-
International normalized ratio
- LA:
-
Left atrium
- LV:
-
Left ventricle
- MRI:
-
Magnetic resonance imaging
- NT-proBNP:
-
N-terminal prohormone of brain natriuretic peptide
- PRISMA:
-
Preferred reporting items for systematic reviews and meta-analysis
- RA:
-
Right atrium
- RV:
-
Right ventricle
- RBBB:
-
Right bundle branch block
- WBC:
-
White blood count
References
Paraskevaidis IA, Michalakeas CA, Papadopoulos CH, Anastasiou-Nana M (2011) Cardiac tumors. ISRN Oncol 2011:208929
Basso C, Valente M, Poletti A, Casarotto D, Thiene G (1997) Surgical pathology of primary cardiac and pericardial tumors. Eur J Cardiothorac Surg 12(5):730–7
Ekmektzoglou KA, Samelis GF, Xanthos T (2008) Heart and tumors: location, metastasis, clinical manifestations, diagnostic approaches and therapeutic considerations. J Cardiovasc Med (Hagerstown) 9(8):769–777
Wang H, Li Q, Xue M, Zhao P, Cui J (2017) Cardiac myxoma: a rare case series of 3 patients and a literature review. J Ultrasound Med 36(11):2361–2366
Bhatia V, Jain C, Ray S, Gupta O, Chatterjee D, Kumar A (2021) Mechanical thrombectomy in embolic cardiac myxoma: case report and literature review. Neurol India 69(3):707–710
Ekinci EI, Donnan GA (2004) Neurological manifestations of cardiac myxoma: a review of the literature and report of cases. Intern Med J 34(5):243–249
Rodríguez Bandera AI, Stewart NC, Uribe P, Minocha R, Choi JYJ (2015) Cutaneous embolism of an atrial myxoma. Australas J Dermatol 56(3):218–220
García-F-Villalta MJ, Sanz-Sánchez T, Aragüés M, Blasco A, Fraga J, García-Diez A (2002) Cutaneous embolization of cardiac myxoma. Br J Dermatol 147(2):379–382
Bernatchez J, Gaudreault V, Vincent G, Rheaume P (2018) Left atrial myxoma presenting as an embolic shower: a case report and review of literature. Ann Vasc Surg 53:266.e13–266.e20
Yuan SM (2012) Mitral valve myxoma: clinical features, current diagnostic approaches, and surgical management. Cardiol J 19(1):105–109
Saputra PBT, Jannah AR, Rofananda IF, Al-Farabi MJ, Wungu CDK, Susilo H et al (2023) Clinical characteristics, management, and outcomes of pulmonary valve myxoma: systematic review of published case reports. World J Surg Oncol 21(1):99
Kuon E, Kreplin M, Weiss W, Dahm JB (2004) The challenge presented by right atrial myxoma. Herz 29(7):702–709
Parums DV (2021) Review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines. Med Sci Monit Int Med J Exp Clin Res 27:e934475–e934481
Abramson N, Melton B (2000) Leukocytosis: basics of clinical assessment. Am Fam Physician 62(9):2053–2060
Pawlotsky Y, Goasguen J, Guggenbuhl P, Veillard E, Jard C, Pouchard M et al (2004) Σ ESR: an erythrocyte sedimentation rate adjusted for the hematocrit and hemoglobin concentration. Am J Clin Pathol 122(5):802–810
Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M et al (2001) C reactive protein in patients with chronic renal diseases. Ren Fail 23(3–4):551–562
Datlow MD, Gray KM, Watts A, Diercks DB, Mumma BE (2017) Troponin limit of detection plus cardiac risk stratification scores to rule out acute myocardial infarction and 30-day major adverse cardiac events in ED patients. Crit Pathw Cardiol 16(4):142–146
Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23(2):60–63. https://doi.org/10.1136/bmjebm-2017-110853
Oktaviono YH, Saputra PBT, Arnindita JN, Afgriyuspita LS, Kurniawan RB, Pasahari D et al (2024) Clinical characteristics and surgical outcomes of cardiac myxoma: a meta-analysis of worldwide experience. Eur J Surg Oncol 50(2):107940
He DK, Zhang YF, Liang Y, Ye SX, Wang C, Kang B et al (2015) Risk factors for embolism in cardiac myxoma: a retrospective analysis. Med Sci Monit Int Med J Exp Clin Res 21:1146
Liu Y, Wang J, Guo L, Ping L (2020) Risk factors of embolism for the cardiac myxoma patients: a systematic review and metanalysis. BMC Cardiovasc Disord 20(1):348
Frizell AW, Higgins GL (2014) Cardiac myxoma as a mimic: a diagnostic challenge. Am J Emerg Med 32(11):1399–1404
Lee VH, Connolly HM, Brown RD (2007) Central nervous system manifestations of cardiac myxoma. Arch Neurol 64(8):1115–1120
Centofanti P, Di Rosa E, Deorsola L, Dato GMA, Patane F, La Torre M et al (1999) Primary cardiac tumors: early and late results of surgical treatment in 91 patients. Ann Thorac Surg 68(4):1236–1241
Frizell AW, Higgins GL III (2014) Cardiac myxoma as a mimic: a diagnostic challenge. Am J Emerg Med 32(11):1399–1404
Bhan A, Mehrotra R, Choudhary SK, Sharma R, Prabhakar D, Airan B et al (1998) Surgical experience with intracardiac myxomas: long-term follow-up. Ann Thorac Surg 66(3):810–813
Colin GC, Gerber BL, Amzulescu M, Bogaert J (2018) Cardiac myxoma: a contemporary multimodality imaging review. Int J Cardiovasc Imaging 34:1789–1808
Pinede L, Duhaut P, Loire R (2001) Clinical presentation of left atrial cardiac myxoma: a series of 112 consecutive cases. Medicine 80(3):159–172
Acknowledgements
None.
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Author information
Authors and Affiliations
Contributions
B.D., R.A.B, M.M.Z., F.S., and M.J. screened the papers and extracted the data. M.R.R. and G.G.D. prepared the draft. All authors read and signed the final paper.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declared they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rabiee Rad, M., Ghasempour Dabaghi, G., Darouei, B. et al. Clinical and laboratory manifestations, ECG findings, and outcomes of right atrial myxoma: a systematic review of cases reported worldwide. Egypt Heart J 76, 125 (2024). https://doi.org/10.1186/s43044-024-00550-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s43044-024-00550-x